BridgeBio Pharma, Inc. (BBIO) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:10 AM EDT
Company Participants
Chinmay Shukla – Senior Vice President of Strategic Finance
Anna Wade – BD & Operations
Julie Everett – Chief Operating Officer of Skeletal Dysplasias
Conference Call Participants
Joshua Schimmer – Cantor Fitzgerald & Co., Research Division
Presentation
Joshua Schimmer
Cantor Fitzgerald & Co., Research Division
Welcome, everyone. I’m Josh Schimmer from the Cantor Biotech Equity Research team. I’m very pleased to introduce from BridgeBio. We have Chinmay Shukla, immediately to my right, SVP of Investor Relations and Strategic Finance. Next to Chinmay, we have Anna Wade, Chief Operating Officer of BridgeBio Neuromuscular. And beside Anna, we have Julie Miller Everett, not Everett Miller, we caught that, Chief Operating Officer of BridgeBio Skeletal Dysplasias. So great to have the team with us.
Question-and-Answer Session
Joshua Schimmer
Cantor Fitzgerald & Co., Research Division
Chinmay, maybe you want to kick things off, give us a quick snapshot of where BridgeBio is today and where the company is headed?
Chinmay Shukla
Senior Vice President of Strategic Finance
Yes. Happy to do that. First, Josh, thank you for hosting us, and thank you to all the investors for joining us here and as well as on our one-on-ones. So BridgeBio today is at an inflection point. We have $8 billion in post-Phase III peak year sales assets. The first of that is Attruby, which is launched, which we think is a $4 billion drug. Globally, it was already annualizing to over $1 billion in 2Q.
So we’re building on our strength there. Right after that, we have 3 launches upcoming very shortly now. I think the first one, limb-girdle is going to be in November. And then we expect to launch in achondroplasia as well as ADH1 sort of early next year. So
